Biopharmaceutical company Scholar Rock Holding Corp (SRRK) recently announced that regarding the resubmission of its Biologics License Application (BLA), the company expects the U.S. Food and Drug Administration (FDA) to accept the filing within 30 days and initiate the formal review process.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity lowers BioNTech's target price to $132
Mirae Asset Global Investments Raises Stake in IGIS Value Plus REIT to 14.45% From 14.44%
The price of tungsten has surged more than sevenfold in two years, and tungsten mining companies are collectively rushing for US stock IPOs.
Over the past two years, combined supply constraints and unleashed demand have driven tungsten prices to epic levels, as global tungsten miners accelerate their entry into the public market.
Canadian Research Overview - Aecon Group, Suncor Energy, Wellstar Technologies
Crypto prices
More
